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Aim: Substance abuse has become a universal crisis in our modern age. Among illegal
substances, opium and its derivatives have been ranked second in terms of usage after
cannabis in the world. In many Asian regions, the use of opium enjoys a high social
acceptance; hence, some common people and even medical practitioners believe that
opium lowers blood glucose and pressure and treat dyslipidemia. How much this belief
is scientifically justified?
Method: The results of available studies on both humans and animals searched in
different search engines up to mid-2016 were integrated (78 articles). Upon the findings
we try to offer a more transparent picture of the effects of opium on the mentioned factors
along with the probable underlying mechanisms of its action.
Results: Taken together, a variety of evidences suggest that the consumption of
opium has no scientific justification for amendment of these biochemical variables. The
mechanisms proposed so far for the action of opium in the three above disorders are
summarized at the end of the article. Short term effects seems to be mostly mediated
through central nervous system (neural and hormonal mechanisms), but long term effects
are often due to the structural and functional alterations in some body organs.
Conclusion: Although opium may temporarily reduce blood pressure, but it increases
blood glucose and most of blood lipids. Moreover its long term use has negative
impacts and thus it aggravates diabetes, dyslipidemia and hypertension. Accordingly,
it is necessary to inform societies about the potential disadvantages of unauthorized
opium consumption.
Keywords: opium, blood glucose, serum lipids, blood pressure, diabetes, dyslipidemia, hypertension, prevalence
INTRODUCTION
Substance abuse is today’s serious health and socio-economic issue (UnitedNations Office onDrugs
and Crime, 2014). Globally, after cannabis, opioids have the highest rate of illicit drug consumption.
United Nations’ Office on Drugs and Crime estimated that in 2013, 32.4 million of the world’s
adult population consumed opioids. Of these, 16.5 million were users of opiates (opium and its
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derivatives specifically heroin). Asia is themost importantmarket
for opiates, and Asian countries have monopolized about two
thirds of the opiates market (United Nations Office on Drugs
and Crime, 2015). One of the reasons for high usage in these
countries might be the easy access to the drug because the
main opium producer countries such as Afghanistan, and to a
less extent, Myanmar, and Laos are located in this continent.
Some Asians believe that opium could have positive impacts on
lowering of serum lipids, blood glucose and blood pressure. Such
a belief has some adherents even among medical practitioners
(Farahani et al., 2008; Jafari et al., 2009). Is this ancient belief
scientifically justified? Over the recent years many studies
have been performed on humans and animals to answer this
question or have reviewed its effects on cardio-metabolic diseases
(Masoudkabir et al., 2013). The objective of present review is
to collect and integrate the newest information with previous
findings to clarify the effects of opium on forenamed biochemical
variables and the underlying mechanisms of the action of opium
on these conditions. In this regards and in addition to the studies
on blood glucose, blood pressure and serum lipids, the effects
of opium on the prevalence of hypertension, dyslipidemia and
diabetes, have also been included. Furthermore, since morphine
is the main alkaloid constituent of opium (see below), and many
physiological and pharmacological effects of opium are ascribed
to morphine, few studies that focus on the impact of morphine
on these disorders are also considered.
Overall the results of animal studies may be more consistent
and reliable because there are less confounding variables in these
studies to affect the results. Therefore, we included the results of
the related animal studies in the review. Some of these variables
that may alter the effect of opium in human include, sex and age
range of subjects, nutritional factors, psycho-social conditions,
physical activity level, concomitant use of other substances such
as alcohol, cigarette, tobacco, and underlying diseases. Therefore,
in this review we firstly address the results of human studies and
then proceed to the results on the animal studies and related
mechanisms.
THE ORIGIN AND INGREDIENTS OF
OPIUM AND THEIR PHARMACOLOGY
Primary opium is a milky latex extracted by scoring unripe
capsules of opium poppy plant (Papaver somniferum). After
being exposed to air, it turns into a dark brown and solidified
substance (Schiff, 2002). In addition to water, various sugars
and several organic acids, around 50 alkaloids have also
been isolated from opium so far and the latter constitute
approximately 20–30% of its raw weight (Schiff, 2002; Najafipour
et al., 2010). Alkaloids are categorized to two main groups
(Phenanthrenes and Benzylisoquinolines) and several minor
groups (Schiff, 2002; European Food Safety Authority, 2011).
Phenanthrenes including morphine, codeine, and thebaine
constitute the predominant psychoactive ingredients (European
Food Safety Authority, 2011). Phenanthrenes and opium derived
semisynthetic drugs such as heroin are termed opiates. All
morphine like analgesics, regardless of their source which
encompass opiates, endogenous opioid peptides and synthetic
opioids constitute the drug class named opioids (Vuong et al.,
2010). Papaverine relaxes smooth muscle and noscapine has
an antitussive property (Kalant, 1997; European Food Safety
Authority, 2011). Morphine is both the most active and the most
copious alkaloid in opiumwith codeine being in the second order
(Schiff, 2002; European Food Safety Authority, 2011). Opioids act
via at least three types of receptors, namedmu (µ), kappa (κ), and
delta (δ) (Vuong et al., 2010). Mostly, opioidµ-receptors mediate
the effects of morphine. Euphoric and analgesic properties are the
most common reasons for the consumption of opium by its users
(Kalant, 1997).
In medical use opioids are essential in the management
of myocardial infarction, severe pain subsequent to surgical
procedures, late-stage cancers, and other torturous diseases and
conditions. Hence, availability of these substances for medical
purposes should be ensured and theirmisuse should be prevented
(United Nations Office on Drugs and Crime, 2014).
The consumption of opium for medical and recreational
purposes has a long history. For inhalation, opium is directly
heated by charcoal or a hot and thin metal rod until the active
alkaloids, particularly morphine, are smoked. During smoking,
a great deal of morphine in the opium is lost. In the oral
method, the bioavailability of morphine is diminished due to
the metabolism in the digestive system and the hepatic first
pass effect, but codeine is less affected (Kalant, 1997; European
Food Safety Authority, 2011). Furthermore, morphine is slowly
absorbed into the bloodstream in the small intestine, thus the
action of oral opium consumption starts after a delay, and the
duration of this action is long. On the contrary, after smoking
opium, the onset of action is fast and intense, and the duration of
the action is shorter (Kalant, 1997).
THE IMPACT OF OPIUM ON BLOOD
GLUCOSE AND DIABETES
Human Studies
Most clinical reports imply that opium has no remarkable impact
on blood glucose (Table 1) whether in non-diabetic (Asgary et al.,
2008; Roohafza et al., 2013; Javadi et al., 2014; Masoomi et al.,
2015; Sanli et al., 2015) or in diabetic individuals (Karam et al.,
2004; Hosseini et al., 2011; Rezvanfar et al., 2011; Najafi and
Sheikhvatan, 2012a; Bayani et al., 2014; Rahimi et al., 2014).
In some of these studies, glycated hemoglobin (HbA1c), as an
indicator of poor control of blood glucose, was significantly
higher in addicted groups (Karam et al., 2004; Asgary et al.,
2008). Another report on the addicted subjects attempting
opium abstention showed that fasting blood glucose (FBS) did
not change considerably 3 months after opium withdrawal
(Mahmoodi et al., 2012). A study on heroin and methadone
addicts indicated that FBS was similar with control group,
but insulin was significantly higher in the addicted groups.
After oral or intravenous glucose load, plasma glucose was
significantly higher and insulin response was significantly lower
in the addicted groups. Authors suggested that insulin response
may be impaired either due to the functional failure of stressed
β-cells or by altering of its action on target tissues (Ceriello
et al., 1987). In another research, after the subjects had a
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TABLE 1 | The studies indicating effects of opium on blood glucose and diabetes.
A—HUMAN STUDIES
Study
reference
Type of substance
and duration of
usage
Type of study Study population Underlying
disease
Results (addicts compared
to non-addicts)
BMI FBS HbA1c Prevalence of
diabetes
Asgary et al.,
2008
Opium addicted Case-control n = 720 smoker men (360
opium addict, 360 non-addict)
None ND ND
Sanli et al., 2015 Opium addicted Case-control n = 115 men/women (46 opium
dependent, 69 non-dependent)
None ND ND ND
Masoomi et al.,
2015
Opium addicted Cross-sectional n = 217 men (103 opium addict,
114 non-addict)
None ND ND
Roohafza et al.,
2013
Opium addicted Cohort n = 569 men (99 opium addicts,
470 non-addicts)
AMI ND ND
Javadi et al.,
2014
Opium addicted Cross-sectional n = 304 men/women (152
opium user, 152 non-user)
AMI ND ND
Bayani et al.,
2014
Opium (for more
Than 6 months)
Cross-sectional n = 97 men/women (48 opium
addicts, 49 non-addicts)
ACS + type 2
diabetes
Both groups
were diabetic
Najafi and
Sheikhvatan,
2012a
Opium addicted Cross-sectional n = 232 (26 opium addicts, 206
non-addicts)
advanced CAD+
type 2 diabetes
Both groups
were diabetic
Karam et al.,
2004
Opium (for at least 1
year)
Case-control n = 98 men/women (49 opium
addict, 49 non-addict)
Type 2 diabetes
#
Both groups
were diabetic
Hosseini et al.,
2011
Opium (for more
than 3 month)
Cross-sectional n =456 men/women (228 opium
addict, 228 non-addict)
Diabetes mellitus ND Both groups
were diabetic
Rahimi et al.,
2014
Opium addicted Cross-sectional n = 374 men/women (179
opium addict, 195 non-addict)
Type 2 diabetes Both groups
were diabetic
Rezvanfar et al.,
2011
Opium addicted Cross-sectional n = 232 men (88 opium user,
144 non-user)
Type 2 diabetes Both groups
were diabetic
Ceriello et al.,
1987
Heroin (for 2–7
years) Methadone
(for 1–3 years)
Case-control n = 45 men (15 heroin addict, 15
methadone treatment, 15
normal)
None ND ND
Zandomeneghi
et al., 1988
Heroin (for at least 2
years)
Case-control n = 20 men/women (10 heroin
addict, 10 normal)
None ND ND
Gozashti et al.,
2015
Opium addicted Case-control n = 108 men/women (53 opium
addict, 55 non-addict)
None ND ND
Azod et al., 2008 Opium addicted Case-control n =69 men (23 opium addict, 46
non-addict)
Type 2 diabetes Both groups
were diabetic
Afarinesh et al.,
2014
Opium (for more
than 2 years)
Cross-sectional n = 320 men (90 opium
dependent, 120 opium
withdrawal, 110 healthy)
None ND ND ND
Shirani et al.,
2010
Opium addicted Cross-sectional n = 939 men (opium addicts,
and non-addicts)
CAD
Masoomi et al.,
2008
Opium addicted Cross-sectional n = 240 men/women (126
opium addict, 114 non-addict)
AMI ND ND
Aghadavoudi
et al., 2015
Opium (for 12.6 ±
7.7 years)
Cross-sectional n = 325 men/women (117
opium addict, 208 non-addict)
CAD ND
Dehghani et al.,
2013
Opium addicted Cross-sectional n = 460 men/women (239
opium addict, 221 non-addict)
AMI ND ND
Divsalar et al.,
2010
Opium, Heroin Cross-sectional n = 112 men (42 opium addict,
35 heroin addict, 35 non-addict)
None
*
ND ND
Najafi and
Sheikhvatan,
2012b
Opium addicted Cross-sectional n = 268 men/women (38 opium
addict, 230 non-addict)
CAD ND ND
Yousefzadeh
et al., 2015
Opium addicted Cross-sectional n = 5332 men/women (811
current opium users, 176 former
opium users. 4340 non-user)
None ND ND
(Continued)
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TABLE 1 | Continued
A—HUMAN STUDIES
Study
reference
Type of substance
and duration of
usage
Type of study Study population Underlying
disease
Results (addicts compared
to non-addicts)
BMI FBS HbA1c Prevalence of
diabetes
Davoodi et al.,
2005
Opium addicted Cohort n = 160 (45 opium-dependent,
115 non-dependent)
AMI ND ND ND
Najafipour et al.,
2015a
Opium addicted Cross-sectional n = 5896 men/women
(non-users, occasional users,
dependent users)
normal/T2DM ND
B—ANIMAL STUDIES
Study reference Animal Type of substance and
duration of usage
Study population Underlying disease Results (addicts compared
to non-addicts)
FBS HbA1c
Mohammadi et al.,
2012
Mouse Opium (orally for 1 month) n = 16 (8 opium addict, 8 non-addict) None ND
Sadeghian et al.,
2009
Rat Opium (orally for 1 month) n = 20 male (10 addict, 10 non-addict) Diabetes mellitus
Mami et al., 2011 Rabbit Opium (orally for 60 days) n = 40 (20 addict, 20 non-addict) None ND
Sadava et al.,
1997
Rat Methadone (orally for 35 days) n = 70 female (35 addict, 35 control) None ND
Symbols: , decrease; , increase; , no difference; #, addicted males compared to control males; *, opium addicted compared to control.
FBS, fasting blood sugar; HbA1c, glycated hemoglobin; ND, not detected; None, no disease; AMI, acute myocardial infarction; CAD, coronary artery disease.
standard meal, FBS was not different between the heroin addicts
and the control group. C-peptide immunoreactivity, however,
was lower and insulin immunoreactivity was higher in the
addicts. It was concluded that heroin addiction may cause β-
cell failure and contemporaneously produce hyperinsulinemia
due to the alteration of the rate of hepatic extraction of insulin
(Zandomeneghi et al., 1988). In one study in opium addicts,
FBS was significantly higher compared to that of the non-addicts
(Gozashti et al., 2015). In this report, the increase of FBS was
accompanied with a significant decrease in the fasting blood
insulin.
In contrast, several reports have indicated that opium has
a positive impact on the fall of FBS. In a study on diabetic
patients, the opium addiction significantly decreased FBS and
2HPP (glucose concentration 2-h post prandial) compared to
the non-addicted patients, but HbA1c did not alter (Azod et al.,
2008). The reduction of 2HPP might be due to the decrease
of gastric emptying due to opioid µ-receptor activation and
thereafter delaying the intestinal glucose absorption (Azod et al.,
2008). Several studies on non-diabetic subjects also showed lower
levels of FBS in opium addicts compared to the non-addicts
(Masoomi et al., 2008; Shirani et al., 2010; Dehghani et al., 2013;
Afarinesh et al., 2014; Aghadavoudi et al., 2015); yet, FBS in the
heroin addicts was similar to that of the non-addicts (Divsalar
et al., 2010).
The findings regarding the prevalence of diabetes are
controversial as well (Table 1). Some studies have demonstrated
the lower rate of diabetes among opium addicts compared to the
non-addicts (Masoomi et al., 2008; Shirani et al., 2010; Najafi
and Sheikhvatan, 2012b; Dehghani et al., 2013; Aghadavoudi
et al., 2015). One study showed the opposite result (Yousefzadeh
et al., 2015), while the data gathered from some other studies
have shown no relation between opium addiction and the
rate of diabetes mellitus (Davoodi et al., 2005; Javadi et al.,
2014; Masoomi et al., 2015). In a more recent population-
based study by the authors of this article on 5900 individuals,
opium consumption had no significant association with diabetes
(Najafipour et al., 2015a), yet the addicted people had a higher
rate of uncontrolled diabetes (Najafipour et al., 2015b).
Animal Studies
In none of the animal studies, opium or opioids decreased blood
glucose (Table 1). In one study on normoglycemic mice, there
was no significant difference in the blood glucose between the
opium addicted group and the control group (Mohammadi et al.,
2012). Moreover, in one study on diabetic rats, regarding serum
glucose, there was no significant difference between the opium
treated and the control group (Sadeghian et al., 2009). Mami
et al. showed that in opium addicted rabbits, serum FBS was
significantly higher compared to that of the non-addicted ones
(Mami et al., 2011). In one study on conscious dogs, intravenous
infusion of morphine had dual effects, low dose (2mg/h) did
not change blood glucose, but high doses (8.16mg/h) caused
hyperglycemia subsequent to the elevation of glucose production
in the liver and reduction of glucose clearance in peripheral
tissues. These effects were attributed to the increased levels
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of epinephrine, glucagon, and cortisol in plasma (Radosevich
et al., 1984). In a similar study done on conscious rabbits, the
administration of 0.3 and 3mg/kg morphine produced the same
results. The authors suggested that hyperglycemia made by high
doses might be a response to the secretion of adrenaline (May
et al., 1988). In the study of Molina et al on rats, central infusion
of morphine significantly raised the blood glucose. These data
indicated that hyperglycemic effects of morphine were mediated
through central nervous system (CNS), and were led to increased
hepatic glucose production secondary to glycogenolysis and in
part due to the decrease of insulin release (Molina et al., 1994).
Likewise, single intravenous injections of morphine (0.5mg/kg)
resulted in more hyperglycemia in diabetic conscious dogs
compared to the normal dogs. This effect of morphine was partly
attributed to the increase of glucagon secretion (Ipp et al., 1980).
Furthermore, in intra-peritoneally opium injected rats, blood
glucose increased gradually between 30 and 120min after the
injection of opium, compared to that of the control group (Asadi
et al., 2008). In one study, the orally methadone therapy in the
rats for a 35-days period by increasing doses (0.5–1.8mg/kg)
raised blood glucose significantly. In this study, blood glucose was
returned back to its normal level 30 days after the withdrawal. In
addition, while being exposed to methadone, the animals showed
impairment in glucose tolerance test (Sadava et al., 1997).
THE IMPACT OF OPIUMONLIPID PROFILE
AND DYSLIPIDEMIA
Human Studies
There is a disparity regarding the impact of opium on lipid
indices in humans (Table 2). Several studies on healthy subjects
and on individuals who suffered from diabetes mellitus, acute
myocardial infarction (AMI) and coronary artery disease (CAD)
have indicated no significant relations between opium addiction
and triglyceride (TG), total cholesterol (TC), low density
lipoprotein (LDL), and high density lipoprotein (HDL) levels
(Azod et al., 2008; Shirani et al., 2010; Najafi and Sheikhvatan,
2012a; Roohafza et al., 2013; Afarinesh et al., 2014; Bayani et al.,
2014; Javadi et al., 2014; Masoomi et al., 2015; Sanli et al., 2015).
On the other hand, some studies have shown that opium
addiction has a harmful effect on one or more lipid parameters.
One study on diabetic patients indicated that HDL significantly
decreased, or prevalence of lowHDL increased in opium addicted
compared to non-addicted patients. Yet, other lipids were not
different between the two groups (Rahimi et al., 2014). In another
study on diabetic patients, HDL was diminished only in men
not in women (Karam et al., 2004). Asgary et al. who carried
out a study on male cigarette smokers also had the same results.
They showed that the ways of opium consumption (smoking or
ingestion) had no impact on its outcomes; however, the duration
of addiction of more than 2 years significantly augmented LDL
(Asgary et al., 2008). Furthermore, in a study on patients who
were candidates for coronary artery bypass grafting, the levels
of LDL and TG were significantly higher in opium addicts than
non-addicts (Aghadavoudi et al., 2015). In another study, it has
been shown that the serum levels of TG, TC, and LDL in opium
addicted individuals were significantly higher (Salman et al.,
2010) or heroin addicts had lower TC and TG, and higher VLDL
than the non-addicts (Akif et al., 2013).
Maccaria et al. indicated that in heroin addicts compared to
the control group, TG increased while TC and HDL decreased
(Maccaria et al., 1991). Furthermore, the frequency of lower
cholesterolemia and low HDL were higher in the addicted group
than the control. The linear regression analysis showed an inverse
correlation between TC and alanine aminotransferase (ALT), an
enzyme found mostly in liver damaged cells. Accordingly, the
researchers suggested that lower cholesterol might be due to
liver disease which is common in heroin addicts (Maccaria et al.,
1991).
Unlike the above studies which demonstrated that opium
addiction has no beneficial effect on plasma lipids, some data
have shown the beneficial effect of opium addiction on such
factors. In two studies on diabetic opium users, the level of
serum TG was significantly lower than the diabetic non-users,
but this was not different with respect to other lipids (Hosseini
et al., 2011; Rezvanfar et al., 2011). In three studies on patients
with AMI, similar results were obtained (Davoodi et al., 2005;
Masoomi et al., 2008; Dehghani et al., 2013). Likewise, Fatemi
et al. compared male opium addicts with male non-addicts. They
observed no significant difference in TG, LDL, and HDL levels
of the two groups, but the total cholesterol level was significantly
less in the opium addicts (Fatemi et al., 2008). This was attributed
to the lower BMI in the opium addicts. Gozashti et al. showed
that TC and HDL significantly decreased in opium addicts, but
TG remained unchanged (Gozashti et al., 2015). Divsalar et al.
indicated that TC was significantly lower in opium and heroin
addicts compared to that of the non-addicts (Divsalar et al.,
2010).
The prevalence of dyslipidemia has also been reported
differently in various studies, so that in some, no association was
found between opium addiction and prevalence of dyslipidemia
(Hosseini et al., 2011; Najafi and Sheikhvatan, 2012a; Bayani
et al., 2014; Javadi et al., 2014; Najafipour et al., 2015a). In a few
researches, the prevalence of dyslipidemia was lower (Maccaria
et al., 1991; Dehghani et al., 2013; Rahimi et al., 2014), and
in some others, the prevalence was higher in opium addicts
(Aghadavoudi et al., 2015). Overall, although opium may reduce
blood lipids in some cases, the majority of human studies have
demonstrated that opium consumption either is ineffective or has
unfavorable impact on serum lipids.
Animal Studies
In comparison to clinical studies, more consistency exists among
data of animal studies. Accordingly, in most of instances, opiates
did not have any useful impact on plasma lipids (Table 2). In
a study on STZ-induced diabetic rats, the lipid profiles were
similar in the opium treated and the control groups (Sadeghian
et al., 2009). In addition, in another study on hamsters, opium
administration had no significant influence on plasma lipids;
however, opium augmented the effect of alcohol in increasing TC,
TG, LDL, VLDL, liver enzymes, and atherogenic index. Opium
raised some oxidative stress indices as well (Mohammadi et al.,
2013). In another study on rats fed with cholesterol enriched
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TABLE 2 | The studies indicating the effects of opium on blood lipids and dyslipidemia.
A—HUMAN STUDIES
Study
reference
Type of
Substance and
duration of
usage
Type of
study
Study population Underlying
disease
Results (addicts compared to
non-addicts)
BMI TG TC LDL HDL Prevalence of
dyslipidemia
Asgary
et al., 2008
Opium addicted Case-control n =720 smoker men (360
opium addict, 360
non-addict)
None ND ND
Sanli et al.,
2015
Opium addicted Case-control n = 115 men/women (46
opium dependent, 69
non-dependent)
None ND ND
Masoomi
et al., 2015
Opium addicted Cross-
sectional
n = 217 men (103 opium
addict, 114 non-addict)
None ND ND ND ND
Roohafza
et al., 2013
Opium addicted Cohort n = 569 men (99 opium
addicts, 470 non-addicts)
AMI ND
Javadi
et al., 2014
Opium addicted Cross-
sectional
n = 304 men/women (152
opium user, 152 non-user)
AMI ND
Bayani
et al., 2014
Opium (for more
Than 6 months)
Cross-
sectional
n = 97 men/women (48
opium addicts, 49
non-addicts)
ACS + type 2
diabetes
Najafi and
Sheikhvatan,
2012a
Opium addicted Cross-
sectional
n = 232 (26 opium
addicts, 206 non-addicts)
advanced CAD+
type 2 diabetes
Azod et al.,
2008
Opium addicted Case-control n =69 men (23 opium
addict, 46 non-addict)
Type 2 diabetes ND
Afarinesh
et al., 2014
Opium (for more
than 2 years)
Cross-
sectional
n = 320 men (90 opium
dependent, 120 opium
withdrawal, 110 healthy)
None ND ND ND ND
Karam
et al., 2004
Opium (for at
least 1 year)
Case-control n = 98 men/women (49
opium addict, 49
non-addict)
Type 2 diabetes ND # ND
Rahimi
et al., 2014
Opium addicted Cross-
sectional
n = 374 men/women (179
opium addict, 195
non-addict)
Type 2 diabetes h
Salman
et al., 2010
Opium addicted Cross-
sectional
n = 53 men/women (29
opium addict, 24
non-addict)
None ND ND
Aghadavoudi
et al., 2015
Opium (for 12.6
± 7.7 years)
Cross-
sectional
n = 325 men/women (117
opium addict, 208
non-addict)
CAD ND
Maccaria
et al., 1991
Heroin addicted Case-control n = 83 men/women (60
addict, 23 non-addict)
None ND
h
c
Gozashti
et al., 2015
Opium addicted Case-control n = 108 men/women (53
opium addict, 55
non-addict)
None ND ND
Hosseini
et al., 2011
Opium (for more
than 3 month)
Cross-
sectional
n =456 men/women (228
opium addict, 228
non-addict)
Diabetes mellitus
Rezvanfar
et al., 2011
Opium addicted Cross-
sectional
n = 232 men (88 opium
user, 144 non-user)
Type 2 diabetes ND
Davoodi
et al., 2005
Opium addicted Cohort n = 160 (45
opium-dependent, 115
non-dependent)
AMI ND ND
(Continued)
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TABLE 2 | Continued
A—HUMAN STUDIES
Study
reference
Type of
Substance and
duration of
usage
Type of
study
Study population Underlying
disease
Results (addicts compared to
non-addicts)
BMI TG TC LDL HDL Prevalence of
dyslipidemia
Masoomi
et al., 2008
Opium addicted Cross-
sectional
n = 240 men/women (126
opium addict, 114
non-addict)
AMI ND ND
Dehghani
et al., 2013
Opium addicted Cross-
sectional
n = 460 men/women (239
opium addict, 221
non-addict)
AMI ND ND
Fatemi
et al., 2008
Opium addicted Case-control n = 175 men (100 opium
addict, 75 non-addict)
None ND
Divsalar
et al., 2010
Opium, Heroin Cross-
sectional
n = 112 men (42 opium
addict, 35 heroin addict,
35 non-addict)
None ND ND ND
Akif et al.,
2013
Opium, Heroin
addicted
Case-control n =125 men (50 opium
addict, 50 heroin addict,
25 non-addict)
None ND *
&
*
&
*
&
ND
Najafipour
et al.,
2015a
Opium addicted Cross-
sectional
n = 5896 men/women
(non-users, occasional
users, dependent users)
None ND ND ND ND
Najafi and
Sheikhvatan,
2012b
Opium addicted Cross-
sectional
n = 268 men/women (38
opium addict, 230
non-addict)
CAD ND ND ND ND
Yousefzadeh
et al., 2015
Opium addicted Cross-
sectional
n = 5332 men/women
(811 current opium users,
176 former opium users.
4340 non-user)
None ND ND ND ND
B—ANIMAL STUDIES
Study
reference
Animal Type of Substance
and duration of usage
Study population Underlying disease Results (addicts compared to
non-addicts)
TG TC LDL HDL
Bryant
et al., 1987
Rat 75mg morphine pellet
(5-days period)
Male rats (morphine group, sham group) Hypercholesterolemia
n
Mami et al.,
2011
Rabbit Opium (orally for 2
months)
n = 40 (20 addict, 20 non-addict) None
Mohammadi
et al., 2013
Hamster Opium (orally for 1
month)
n = 24 male (6 control, 6 opium addict, 6
alcoholic, 6 opium addict and alcoholic)
None b b b
Najafipour
et al., 2010
Rabbit Opium (smoking for 3
days or 28 days)
n = 40 (7 control, 7 isoproterenol, 6 short-term
opium, 6 short-term opium + isoproterenol, 6
long-term opium, 6 long-term opium +
isoproterenol)
Hypercholesterolemia r
Sadeghian
et al., 2009
Rat Opium (orally for 1
month)
n = 20 male (10 addict, 10 non-addict) Diabetes mellitus ND
Mohammadi
et al., 2009
Rabbit
(male)
Opium (orally for 3
months)
n = 28 (7 control, 7 hypercholesterolemic, 7
addicted, 7 hypercholesterolemic-addicted
None
Y
n
Y
n
Y
n
Mohammadi
et al., 2012
Mouse Opium (orally for 1
month)
n = 16 (8 opium addict, 8 non-addict) None ND
Symbols: , decrease; , increase; , no difference; #, addicted males compared to control males; *, opium addicted compared to control; &, heroin addicted compared to control;
n, normocholesterolemia compared to control; y, hypercholesterolemia compared to control; r, chronic opium compared to control; B, both opium addict and alcoholic compared to
control; H, HDL; c, total cholesterol.
ND, not detected; AMI, acute myocardial infarction; CAD, coronary artery disease; ACS, acute coronary syndrome; BMI, body mass index.
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diet, the implantation of a morphine pellet (75mg) for a 5-
days duration raised serum levels of TC, LDL, VLDL, and aortic
cholesterol content, and it decreased HDL level. Moreover, in
normal diet rats, morphine elevated TC, LDL, and VLDL. All of
these effects were prevented by application of opioid antagonist
naltrexone (Bryant et al., 1987). In accordance with these data,
the oral treatment of mice by morphine during a 28-days period
increased liver, aorta and plasma TC levels (Bryant et al., 1988).
In another study, hypercholesterolaemic rabbits were exposed
to opium smoke for a short period (3 days) and a longer
period (28 days). Of these schedules, long term opium smoking
diminished the HDL level and caused a trend of increase in LDL
(Najafipour et al., 2010). In one study on rats, acute morphine
administration resulted in significant increase of the level of
plasma TG compared to the control group, but the other lipids
were unchanged (Al Sagair, 2005). Mami et al. observed that the
oral opium treatment of rabbits for 2 months elevated serum
levels of TC, TG, LDL and liver enzymes compared to the control
group in spite of the fact that weight gaining and abdominal fat
were lower in the opium addicts (Mami et al., 2011). The data
of another study showed that opium consumption in rabbits fed
with cholesterol-rich diet (for 3 months), significantly intensified
the impact of high cholesterol diet on the increase of plasma
levels of TG, TC, and LDL. Yet, in the addicted rabbits without
cholesterol-rich diets, it decreased the plasma concentrations
of TC and LDL (Mohammadi et al., 2009). In another study
conducted by Mohammadi et al., it was shown that the mice fed
with opium for 1 month had significantly lower total cholesterol
compared to the control group, but the two groups had no
difference with respect to other lipids (Mohammadi et al., 2012).
THE IMPACT OF OPIUM ON BLOOD
PRESSURE AND HYPERTENSION
Human Studies
In human studies (Table 3), the intravenous injection of
morphine via central sympathetic inhibition (sympatholysis)
produced vasodilatation (Mansour et al., 1970), but in some
studies, there was no significant difference between opium
dependents and non-dependents with respect to blood pressure
(Roohafza et al., 2013; Aghadavoudi et al., 2015). Furthermore,
in a study on diabetic patients undergoing coronary angiography
before matching of opium users with non-users for age, sex, and
smoking status, the results showed that systolic and diastolic
blood pressure were lower in the opium users. Yet after matching,
no significant differences was observed between the two groups
(Hosseini et al., 2011).
The data on the prevalence of hypertension are different
(Table 3). Most studies indicated that opium addiction had no
significant relation with the rate of hypertension (Davoodi et al.,
2005; Masoomi et al., 2008, 2015; Hosseini et al., 2011; Najafi
and Sheikhvatan, 2012a,b; Roohafza et al., 2013; Bayani et al.,
2014; Javadi et al., 2014; Rahimi et al., 2014). In addition, in
a more recent population-based study by the authors of this
article on 5900 adult individuals, opium use had no significant
association with hypertension in either occasional or dependent
users (Najafipour et al., 2014, 2015a). One study revealed that
hypertension was significantly more prevalent in opium users
than non-users (Yousefzadeh et al., 2015) while some studies
showed the opposite results (Shirani et al., 2010; Dehghani et al.,
2013; Aghadavoudi et al., 2015).
Animal Studies
In anesthetized rats, intravenous injection of the first dose of
morphine (0.025–100 mg/kg) led to fall in their blood pressure,
which was transient, and BP immediately returned to near
normal (Table 3). This reduction was ascribed both to vagal
bradycardia and the decrease in sympathetic tone. After the first
and the second injection however, in dose of 100 mg/kg, the
acute phase was followed by slow falling of BP (Fennessy and
Rattray, 1971). In another study on spontaneously hypertensive
rats, the infusion of morphine lessened BP via vasodilatation. The
response was reversed by the injection of naloxone methiodide.
It was shown that the effectis mediated by peripheral opioid
receptors (Ba˛dzyn´ska et al., 2016). Furthermore, in anesthetized
dogs, intravenous administration of two opioid drugs (fentanyl
and dextromoramide) resulted in hypotension and bradycardia,
which were attributed to a reduced sympathetic tone (Laubie
et al., 1974). Furthermore, the subcutaneous injection of
morphine in cats or injection in to cisterna magna of their brain
caused hypotension and bradycardia due to the inhibition of
sympathetic tone (Feldberg and Wei, 1986). However, the rats
treated by Intra-cerebroventricular (i.c.v) infusion of morphine
or morphine-6-glucuronide showed no change in their arterial
blood pressure (Molina et al., 1994). In one study, oral chronic
treatment of rats with morphine prevented the elevation of blood
pressure subsequent to social deprivation-induced stress. The
authors suggested that chronic treatment bymorphine caused the
desensitization of opioid receptors (Jimenez and Fuentes, 1993).
Conversely, in conscious rabbits, the intravenous administration
of morphine raised BP via increasing sympathetic activity and
serum adrenaline. These effects were blocked by naloxone (May
et al., 1988). In a study on rabbits, short (3 days) and long-term
(4 weeks) exposure of the animals to opium smoke caused a
continuous trend of increase in blood pressure during 4 weeks
(Najafipour et al., 2010).
THE MECHANISMS OF ACTION
The mechanisms proposed so far for the action of opium
on the three above biochemical factors are summarized in
Figure 1. Short term effects are mostly exerted via hormonal and
neural mechanisms, but long term effects are often due to the
structural and functional alterations. In long term, depending
on consumption dose and duration and other factors, different
mechanisms are gradually involved. As it was mentioned before,
acute hyperglycemic effects of morphine were mediated through
CNS, leading to glycogenolysis and decrease of insulin release
(Molina et al., 1994). This response is exaggerated in diabetic
states that have been attributed to the increase of glucagon
secretion (Ipp et al., 1980). In addition, insulin resistance with
opiate use may be coupled with β-cell dysfunction. It has
been shown that in response to an intravenous glucose load,
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TABLE 3 | The studies indicating the effect of opium on blood pressure and hypertension.
A—HUMAN STUDIES
Study
reference
Type of Substance
and duration of
usage
Type of study Study population Underlying
disease
Results (addicts compared to
non-addicts)
BMI BP Prevalence
of hypertension
Roohafza et al.,
2013
Opium addicted Cohort n = 569 men (99 opium addicts,
470 non-addicts)
AMI ND
Hosseini et al.,
2011
Opium Cross-sectional n =456 men/women (228 opium
addict, 228 non-addict)
Diabetes mellitus
Aghadavoudi
et al., 2015
Opium (for 12.6 ± 7.7
years)
Cross-sectional n = 325 men/women (117 opium
abuser, 208 non-abuser)
CAD
Rahimi et al.,
2014
Opium addicted Cross-sectional n = 374 men/women (179 opium
user, 195 non-user)
Diabetes mellitus
Masoomi et al.,
2015
Opium addicted Cross-sectional n = 217 men (103 opium addict,
114 non-addict)
None ND
Mansour et al.,
1970
Morphine (15 mg/kg
single dose)
Inter-ventional Not reported None ND ND
Yousefzadeh
et al., 2015
Opium (for 11.8 years) Cross-sectional n = 5332 men/women (811 current
opium users, 176 former opium
users. 4340 non-user)
None ND
Bayani et al.,
2014
Opium (for more Than
6 months)
Cross-sectional n = 97 men/women (48 opium
addicts, 49 non-addicts)
ACS + type 2
diabetes
ND
Najafi and
Sheikhvatan,
2012a
Opium addicted Cross-sectional n = 232 (26 opium addicts, 206
non-addicts)
advanced CAD+
type 2 diabetes
ND
Javadi et al.,
2014
Opium addicted Cross-sectional n = 304 men/women (152 opium
user, 152 non-user)
AMI ND ND
Najafipour
et al., 2015a
Opium addicted Cross-sectional n = 5896 men/women (non-users,
occasional users, dependent users)
None ND
Davoodi et al.,
2005
Opium Cohort n = 160 (45 opium-dependent, 115
non-dependent)
AMI ND ND
Shirani et al.,
2010
Opium addicted Cross-sectional n =939 men/women(opium
addicts, and non-addicts)
CAD ND
Masoomi et al.,
2008
Opium Cross-sectional n = 240 men/women (126 opium
addict, 114 non-addict)
AMI ND ND
Dehghani et al.,
2013
Opium Cross-sectional n = 460 men/women (239 opium
addict, 221 non-addict)
AMI ND ND
Najafi and
Sheikhvatan,
2012b
Opium addicted Cross-sectional n = 268 men/women (38 opium
addict, 230 non-addict)
CAD ND
B—ANIMAL STUDIES
Study reference Animal Type of substance and duration of
usage
Study population Underlying
disease
Results (drug recipients
compared to themselves or
non-recipients)
Blood pressure
Fennessy and
Rattray, 1971
Rat Morphine (IV injection of different
doses repeatedly at 20 min intervals)
n =48 male/female rats None
Ba˛dzyn´ska et al.,
2016
Rat IV infusion of Morphine (1.5 mg/kg/h)
or biphalin (150 µg/kg/h) for 30 min
n = 36 male (normotensive,
spontaneously hypertensive rats)
Spontaneously
hypertensive
Feldberg and Wei,
1986
Cat Morphine injection (SC or into some
regions of brain)
n = 14 male/female cats None
Jimenez and
Fuentes, 1993
Rat Morphine (orally for 15 days) n =26 male (group housed + vehicle,
isolated + vehicle, group housed +
morphine, isolated + morphine)
Isolation
stress
Symbols: , decrease; , increase; , no difference.
BP, blood pressure; ND, not detected.
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opiate addicts had a 42% lower insulin response, accompanied
by an 80% lower glucose reduction rate than non-addicted
subjects (Ceriello et al., 1987). Moreover, increased fasting insulin
levels in addicted subjects were also observed. In addition
elevation of glucose utilization and the reduction of hepatic
gluconeogenesis subsequent to the activation of peripheral
opioid µ-receptors and the modification of genes involved in
glucose metabolism (Liu and Cheng, 2011) are among suggested
mechanisms. The reduction of 2-h post prandial glucose (2HPP)
in diabetic addicted individuals (Azod et al., 2008) might be
due to the decrease of gastric emptying due to opioid µ-
receptor activation and thereafter delaying the intestinal glucose
absorption. Moreover, the presence of underlying diseases and
probable effects of medicines taken by the subjects may also
come into play. In some reports despite normal glucose levels in
opium addicts, there were hyperinsulinemia along with altered
glucose metabolism similar to what occurs in type 2 diabetes
(Sheldon and Quin, 2005). In animals however, the mechanisms
such as increment of adrenalin, noradrenaline, cortisol, glucagon,
etc., have been involved in increasing blood glucose (Radosevich
et al., 1984). The lower FBS reported in some studies in addicted
individuals has been ascribed to the anorexia secondary to opium
use that cause decrease in body mass index (BMI) and insulin
resistance.
Regarding the effect on blood pressure, morphine is a
vasodilator in human although not through opioid receptors
(OPRs), but through histamine-modulation of nitric oxide (NO)
release (Headrick et al., 2012). This response is also dysregulated
in diabetes (Afshari et al., 2009). Kappa-OPR agonist mediated
reduction in systolic pressure has also been reported to be
reduced in chronic hypertension (Bolte et al., 2009). This seems
to beOPR- andK+ channel-independent, and it is less dependent
upon L-type Ca++ channel function (Guo et al., 2007). Overall,
it seems that the effect of opium on blood pressure is related
to the dose and duration of drug consumption. Low dose
and short term opium administration often decreases blood
pressure and the effect is exerted via vasodilatation and reduction
of sympathetic tone. In long term, the effect of opium on
the reduction of blood pressure is reduced and a trend of
increase in blood pressure supervenes (Joukar et al., 2010). The
increase of plasma homocysteine and fibrinogen (Masoomi et al.,
2002, 2015; de Luis et al., 2005) that predisposes the addicted
persons to a higher risk of blood clotting, atheroma formation
and resultant vascular narrowing may involve in long term
effects. Homocysteine by itself is a risk factor for developing
atherosclerosis and pathological changes in vascular function,
especially in diabetes (de Luis et al., 2005). Overall, it is concluded
that opium not only has no ameliorating effect on hypertension,
but also it is a risk factor for cardiovascular diseases.
Regarding the mechanism of the effect of opium on blood
lipids, some probable mechanisms proposed are reduction of
hepatic clearance of LDL cholesterol from the plasma and
augmenting hepatic synthesis of triglycerides, leading to the
elevated levels of total cholesterol (TC) and triglycerides (TG),
respectively (Bryant et al., 1988). Since lipids can penetrate
blood brain barrier, they may have a role in the CNS associated
with drug addiction (Hillard, 2005). However, it is not clear
whether the lower level of TC (Divsalar et al., 2010; Mohammadi
et al., 2013) and TG (Hosseini et al., 2011; Rezvanfar et al.,
2011) in opium addicts reported in some studies are result of
opium consumption or they are cause for opium addiction.
Some of the authors attributed these to the lower BMI in
the opium addicts. Gozashti et al. showed that TC and HDL
significantly decreased in opium addicts, but TG remained
unchanged (Gozashti et al., 2015). In this regards, feeding
hypercholesterolaemic rabbits with opium caused an increase in
the levels of TC, TG, and LDL cholesterol whereas these variables
decreased in normocholestrolaemic rabbits (Mohammadi et al.,
2009). In another study by the authors on hypercholesterolaemic
rabbits that were exposed to opium smoke, a fall in HDL-
cholesterol was found with no significant effect on the other
lipids (Najafipour et al., 2010). Therefore, the route of opium
consumption (enteral vs. inhalation) might have affected the
impact of opium on lipid profile. In human studies, in a
recent population-based study, opium use had no significant
association with abnormal level of HDL and TG (Yousefzadeh
et al., 2015).
Overall the results of animal studies may be more consistent
and reliable because in clinical studies, some conditions may be
different between addicts and non-addicts that may affect the
results. Some of these factors include:
(1) Nutritional factors: Many addicts lost their jobs and had to
pay extra expenses to provide their required substance. This
led opium users to suffer from malnutrition and vitamin
deficiency. Also, the use of opiates suppresses appetite and
reduces weight in many instances (Divsalar et al., 2010).
Therefore, the reduction of lipids in some studies might be
due to weight loss or nutrient deficiency not owing to direct
effect of opium.
(2) Individual factors such as underlying diseases, psycho-
social problems, physical activity level, and age range of
subjects may alter the effect of opium on serum lipids.
Also these conditions may alter serum biochemical variables
independent of the effect of opium.
(3) Factors relevant to the substance including purity and
ingredients of opium, concomitant use of other substances
(alcohol, cigarette, tobacco,...), duration, quantity and
method of usage. Opioids have negative impact on many
organs such as liver. Opioids are mainly metabolized in
the liver, hence chronic consumption of the substance leads
to serious liver damage. It has been demonstrated that
chronic administration of morphine causes the suppression
of hepatic antioxidant system, elevation of oxidant indices
and induction of apoptosis in hepatocytes in mice (Zhang
et al., 2004; Payabvash et al., 2006). It has also been shown
that there is a direct association between the duration of
heroin consumption and the severity of liver injury in heroin
abusers (Zhang et al., 2004; Ilic´ et al., 2005). Since liver plays a
pivotal role in the metabolism of lipids, chronic liver diseases
are associated with significant alterations in serum lipids
(Ooi et al., 2005; Ghadir et al., 2010).
(4) The factors relevant to research: Many human studies
have small sample sizes or are hospital-based instead
of population-based. Therefore, the results may not be
generalized to the whole population.
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FIGURE 1 | The mechanisms proposed so far for the action of opium on blood glucose, serum lipids, and blood pressure. Herein, short term effects are
mostly exerted via hormonal and neural mechanisms but long term effects are often due to structural and functional alterations. In long-term periods depending on the
dose and duration of use and other factors, different mechanisms are gradually involved. 1Molina et al. (1994), 2Berglund et al. (1990), 3Al Sagair (2005), 4Bryant et al.
(1987), 5Payabvash et al. (2006), 6Zhang et al. (2004), 7Divsalar et al. (2010), 8Rahimi et al. (2014), 9Bryant et al. (1988), 10Radosevich et al. (1984), 11May et al.
(1988), 12 Ipp et al. (1980), 13Molina et al. (1994), 14Zandomeneghi et al. (1988), 15Liu and Cheng (2011), 16Sheldon and Quin (2005), 17Headrick et al. (2012),
18Mansour et al. (1970), 19Asgary et al. (2008), 20de Luis et al. (2005), 21Jimenez and Fuentes (1993), 22Bolte et al. (2009).
Although a large body of evidences is available from human
studies regarding the impact of opium consumption on cardio-
metabolic disorders, however most of these studies are cross
sectional in their design. Limitations of the cross-sectional
studies are simultaneous data collection concerning risk
factors and outcomes which prevents an exact examination
of the temporal transposition between them. In other words,
it cannot be said for sure whether the higher prevalence of
disorders in opium users is the result of opium consumption
or the cause for opium consumption. Therefore, it is
suggested that more prospective longitudinal studies with
large sample sizes to be conducted to clear this temporal
precedence and to identify the pathophysiological mechanisms
more precisely.
CONCLUSION
In spite of the fact that the results of the studies into the effect
of opium on blood glucose, blood lipids and blood pressure are
relatively incoherent, these findings, not only do not support
the traditional beliefs about beneficial effects of opium and
its derivatives on diabetes, dyslipidemia and hypertension, but
they also represents their long term detrimental effects on these
disorders and on many body organs. Therefore, public awareness
about these destructive effects of unauthorized use of opium
would have an important role in health of individuals and the
society.
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